This offering provides a single-institution proposal for Phase II and III development of anti-cancer agents. The University of Texas M.D. Anderson is comprised of disease-specific clinical cancer teams lead by physicians who have extensive backgrounds in the development of antineoplastic agents. These clinical teams include physicians involved in the treatment of melanomas, sarcomas, breast, gynecological, gastrointestinal, lung, head and neck, genitourinary, and neurological malignancies. Specific physician teams provide expertise in designing clinical trials in bone marrow transplantation and in the treatment of leukemias and lymphomas. To understand the basic science of anti-cancer agents under development at athe institution, laboratory correlative studies teams interact closely with the above clinical investigators. Areas of correlative laboratory investigation include analytical biochemistry, pharmacokinetic/pharmacodynamic studies, immunopharmacology, cellular pharmacology, cellular toxicity/lethality, and polyamine synthesis and inhibition. The clinical cancer and laboratory correlative studies teams are supported by a data management/quality control team which is comprised of a clinical trials support core (clinical trials administration, data management and quality assurance, data management support, and scientific=c review committee), biostatistics, and a research pharmacy (clinical materials handling and radiopharmaceuticals). Through the collaborative interaction of the above three teams, new anticancer agents which have undergone Phase I testing are further developed. The proposal provides a mechanism to determine the spectrum of activity of selected agents across a variety of human cancers, establish the role of new agents (or analogues), alone or in combination, and compare this role with standard therapies. In addition, approaches to Phase II/III development of high dose therapy using colony-stimulating factors, peripheral stem cells, or autologous bone marrow support are provided.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
1U01CA070172-01
Application #
2114116
Study Section
Special Emphasis Panel (NSS)
Project Start
1995-08-01
Project End
1999-03-31
Budget Start
1995-08-01
Budget End
1996-03-31
Support Year
1
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Radiation-Diagnostic/Oncology
Type
Other Domestic Higher Education
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Chen, Lei L; Chen, Xinjian; Choi, Haesun et al. (2012) Exploiting antitumor immunity to overcome relapse and improve remission duration. Cancer Immunol Immunother 61:1113-24
Blanke, Charles D; Rankin, Cathryn; Demetri, George D et al. (2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26:626-32
Heinrich, Michael C; Owzar, Kouros; Corless, Christopher L et al. (2008) Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Gr J Clin Oncol 26:5360-7
Chen, Lei L; Holden, Joseph A; Choi, Haesun et al. (2008) Evolution from heterozygous to homozygous KIT mutation in gastrointestinal stromal tumor correlates with the mechanism of mitotic nondisjunction and significant tumor progression. Mod Pathol 21:826-36
Choi, Haesun; Charnsangavej, Chuslip; Faria, Silvana C et al. (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25:1753-9
Benjamin, Robert S; Choi, Haesun; Macapinlac, Homer A et al. (2007) We should desist using RECIST, at least in GIST. J Clin Oncol 25:1760-4
Beinart, Garth A; Gonzalez-Angulo, Ana M; Broglio, Kristine et al. (2007) Phase II trial of 10-EDAM in the treatment of metastatic breast cancer. Cancer Chemother Pharmacol 60:61-7
Chen, Lei L; Sabripour, Mahyar; Andtbacka, Robert H I et al. (2005) Imatinib resistance in gastrointestinal stromal tumors. Curr Oncol Rep 7:293-9
Chen, Lei L; Sabripour, Mahyar; Wu, Elsie F et al. (2005) A mutation-created novel intra-exonic pre-mRNA splice site causes constitutive activation of KIT in human gastrointestinal stromal tumors. Oncogene 24:4271-80
Choi, Haesun; Charnsangavej, Chuslip; de Castro Faria, Silvana et al. (2004) CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol 183:1619-28

Showing the most recent 10 out of 19 publications